In the August edition of the Journal of Drugs in Dermatology (JDD), we turn our focus to psoriasis, one of the most challenging and impactful dermatological conditions. This month’s Editor’s Picks showcase a series of in-depth studies and expert discussions that explore the latest advancements in psoriasis treatment, real-world effectiveness, and the broader implications of the disease on patients’ lives.
Leading our selection is the article Real-Life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study. This compelling study follows 54 patients over two years, offering critical insights into the long-term outcomes of Guselkumab treatment.
This month’s featured podcast, Efficacy and Safety of Secukinumab in the Treatment of Psoriasis in Patients With Skin Phototypes IV to VI, delves into the patient-reported outcomes and highlights the need for larger studies to better understand treatment efficacy across diverse skin types.
Also included in this special psoriasis-focused edition are:
-
- Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel, where a panel of experts compared research from 15 articles to formulate five consensus statements and recommendations on the use of Bimekizumab in treating plaque psoriasis.
- Tildrakizumab Real-World Effectiveness and Safety Over 64 Weeks in Patients With Moderate-to-Severe Plaque Psoriasis: Reporting significant findings from a Phase 4 study, this article offers valuable data on the long-term use of Tildrakizumab.
- Challenges in Adult Acne and the Role of Skin Care in Managing the Condition: While not directly related to psoriasis, this piece underscores the importance of comprehensive acne treatment, highlighting parallels in chronic skin condition management.
- The Hidden Costs of Psoriasis: A Population-Based Study Evaluating How Psoriasis Severity Impacts Work Absenteeism: This study discusses the often-overlooked physical and emotional burdens of psoriasis and how they can affect a patient’s professional life.
- Polymorphous Light Eruptions Treated With Roflumilast 0.3% Cream: A Case Report: Sharing results from what may be a first-of-its-kind treatment, this report adds to the growing body of knowledge on managing complex dermatologic conditions.
- Palmoplantar Pustulosis: Therapy Update: This unrestricted access article analyzes nearly 400 studies to provide a comprehensive update on therapeutic options that show promise in treating this stubborn condition.
Explore this month’s Editor’s Picks to stay informed about the latest research, treatment advancements, and expert opinions in the field of psoriasis. Dive into these articles and gain valuable insights that can enhance your understanding and approach to managing this pervasive dermatological challenge.
Find more JDD Issue Highlights here.
